You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Claims for Patent: 11,752,137

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,752,137

Title:	Ophthalmic compositions for treating ocular Demodex using lotilaner formulations
Abstract:	Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Inventor(s):	Bobak Robert Azamian, Douglas Michael Ackermann, Shawn D. Hickok, Joseph G. Vehige
Assignee:	Tarsus Pharmaceuticals Inc
Application Number:	US17/873,698
Patent Claims:	1. An ophthalmic composition comprising lotilaner and a pharmaceutically acceptable vehicle, wherein the ophthalmic composition is in eye drop form, wherein the ophthalmic composition is sterile and nonirritating to the eye, and wherein the lotilaner is present from about 0.10% to about 0.50% by weight with respect to the total weight of the composition. 2. The ophthalmic composition of claim 1, wherein the pharmaceutically acceptable vehicle further comprises a preservative agent. 3. The ophthalmic composition of claim 1, wherein the lotilaner is the sole active ingredient of the ophthalmic composition. 4. The ophthalmic composition of claim 1, wherein the ophthalmic composition does not comprise tea tree oil. 5. The ophthalmic composition of claim 1, wherein the ophthalmic composition further comprises castor oil. 6. The ophthalmic composition of claim 5, wherein the castor oil comprises hydrogenated castor oil. 7. The ophthalmic composition of claim 1, comprising from between about 0.15% and about 0.40% of the lotilaner by weight with respect to the total weight of the composition. 8. The ophthalmic composition of claim 6, comprising about 0.25% of the lotilaner by weight with respect to the total weight of the composition. 9. The ophthalmic composition of claim 1, wherein the ophthalmic composition is formulated to be topically administered at least once daily for at least about 4 weeks. 10. The ophthalmic composition of claim 8, wherein the ophthalmic composition is formulated to be topically administered at least twice daily for at least about 4 weeks. 11. The ophthalmic composition of claim 9, wherein the ophthalmic composition is formulated to be topically administered at least twice daily for at least about 6 weeks. 12. The ophthalmic composition of claim 1, wherein the ophthalmic composition is formulated to be topically administered in a volume of between 25-50 microliters at least one time daily. 13. The ophthalmic composition of claim 1, wherein the ophthalmic composition is formulated to be topically administered in a volume of between 25-50 microliters at least twice daily for at least six weeks. 14. The ophthalmic composition of claim 1, wherein the ophthalmic composition is for use in treating an ocular Demodex infestation in a human patient. 15. The ophthalmic composition of claim 14, wherein the ocular Demodex infestation comprises blepharitis. 16. The ophthalmic composition of claim 14, wherein the ocular Demodex infestation comprises ocular rosacea. 17. The ophthalmic composition of claim 14, wherein the ocular Demodex infestation comprises Meibomian gland dysfunction. 18. The ophthalmic composition of claim 14, wherein the ocular Demodex infestation comprises ocular surface disease. 19. The ophthalmic composition of claim 14, wherein the ocular Demodex infestation comprises dry eye disease. 20. The ophthalmic composition of claim 14, wherein the ocular Demodex infestation comprises madarosis.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.